Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)

NCT ID: NCT01176227

Last Updated: 2011-04-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 128 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2011-02-28

Brief Summary

The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disorder that is estimated to affect 30% of the general population. IBS is characterized by abdominal pain and cramps, and bowel dysfunction such as diarrhea and bloating.

The medicines that are currently used to help people with IBS are not as effective as we would like them to be. These medicines are usually only prescribed to reduce the pain of IBS and not actually treat the disorder itself. Recently, scientists have found that probiotics (beneficial bacteria that live inside humans) may help reduce the painful symptoms and diarrhea that are part of IBS.

This research is being conducted to determine whether this particular combination of three probiotic bacteria (named Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum) will reduce the symptoms of IBS.

Detailed Description

The purpose of this trial is to investigate the effects of the three strain probiotic, Kyo-Dophilus, on the symptoms associated with Irritable Bowel Syndrome.

The primary objective of this trial is to determine the effectiveness of Kyo-Dophilus on the symptoms associated with Irritable Bowel Syndrome in an adult population diagnosed with Irritable Bowel Syndrome by ROME III criteria and classified as mild through the Irritable Bowel Severity Scoring System and to measuring quality of life and global well being of patients through the Visual Analog Scale and the Irritable Bowel Syndrome-Quality of Life Questioner. The secondary objective is to assess the tolerability of the treatment through the use of study diaries.

Conditions

Irritable Bowel Syndrome; Digestive System Diseases; Colonic Diseases, Functional; Colitis, Mucous; Colon, Irritable

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Kyodophilus matching placebo capsules

Group Type: PLACEBO_COMPARATOR

Kyodophilus Matching Placebo Capsules

Intervention Type: DIETARY_SUPPLEMENT

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Kyodophilus multi strain probiotic capsules

Group Type: ACTIVE_COMPARATOR

Kyodophilus multi-strain probiotic capsules

Intervention Type: DIETARY_SUPPLEMENT

The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:

• Lactobacillus gasseri KS-13 1.2
• Bifidobacterium bifidum G9-1 0.15
• Bifidobacterium longum MM-2 0.15

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Interventions

Kyodophilus multi-strain probiotic capsules

The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:

• Lactobacillus gasseri KS-13 1.2
• Bifidobacterium bifidum G9-1 0.15
• Bifidobacterium longum MM-2 0.15

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Intervention Type: DIETARY_SUPPLEMENT

Kyodophilus Matching Placebo Capsules

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Male and female subjects aged 18-64
• A diagnosis of Irritable Bowel Syndrome as per ROME III criteria
• A classification of mild irritable bowel syndrome as indicated by the Irritable Bowel Severity Scoring System (score >75)
• Female subjects currently using an acceptable form of birth control who agree to maintain its use throughout the study (e.g. abstinence, oral contraceptives, barrier methods)
• Subjects who agree to maintain their current eating habits throughout the study
• Ability to understand and sign the Informed Consent Form

Exclusion Criteria

• Female subjects who are breastfeeding, pregnant, or are open to becoming pregnant in the next three months
• Subjects currently receiving medication for the treatment of IBS symptoms
• Subjects currently receiving natural health products for treatment of IBS symptoms will be eligible for inclusion in the trial is they agree to undergo a two week washout period
• Subjects currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain
• Subjects who are immune-compromised (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment)
• Subjects currently receiving antibiotic therapy or antibiotic therapy within the previous month
• Subjects regularly consuming probiotic containing products (e.g. yogurts, etc.)
• Subjects who have recently (< 3 months) initiated dietary measures to control IBS symptoms
• Subjects with a history of major or complicated gastrointestinal surgery
• Subjects with severe endometriosis
• Subjects with malignant tumors or subjects undergoing chemotherapy or radiation therapy
• Subjects with severe IBS and that require medication
• Subjects with weight loss, anaemia, inflammatory bowel disease, celiac sprue, family history of colorectal cancer
• Subjects exhibiting or indicating thoughts of suicide currently or in the past as based on patient screening interview by the investigator/clinician. Appropriate referral to a health care provider will be provided
• Subjects with known allergies to milk or milk based products
• Subjects using and/or have used antipsychotic or anticholinergic medication within the prior month, those with reported significant abnormalities on the thyroid function tests, blood counts and serum chemistry
• Subjects 50 years or older who have been diagnosed with IBS and have not received a colonoscopy in the last five years.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wakunaga Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Dicentra Inc.

INDUSTRY

Sponsor Role: collaborator

The Canadian College of Naturopathic Medicine

OTHER

Sponsor Role: lead

Responsible Party

The Canadian College of Naturopathic Medicine

Principal Investigators

Dugald Seely, ND

Role: PRINCIPAL_INVESTIGATOR

The Canadian College of Naturopathic Medicine

Locations

The Canadian College of Naturopathic Medicine

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

1001

Identifier Type: -

Identifier Source: org_study_id